Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.

MLA

Shore, Neal D., et al. “Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.” Oncologist, vol. 29, no. 7, July 2024, pp. 581–88. EBSCOhost, https://doi.org/10.1093/oncolo/oyae019.

APA

Shore, N. D., Gratzke, C., Feyerabend, S., Werbrouck, P., Carles, J., Vjaters, E., Tammela, T. L. J., Morris, D., Aragon-Ching, J. B., Concepcion, R. S., Emmenegger, U., Fleshner, N., Grabbert, M., Lietuvietis, V., Mahammedi, H., Cruz, F. M., Paula, A., Pieczonka, C., Rannikko, A., & Richardet, M. (2024). Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS. Oncologist, 29(7), 581–588. https://doi.org/10.1093/oncolo/oyae019

Chicago

Shore, Neal D, Christian Gratzke, Susan Feyerabend, Patrick Werbrouck, Joan Carles, Egils Vjaters, Teuvo L J Tammela, et al. 2024. “Extended Safety and Tolerability of Darolutamide for Nonmetastatic Castration-Resistant Prostate Cancer and Adverse Event Time Course in ARAMIS.” Oncologist 29 (7): 581–88. doi:10.1093/oncolo/oyae019.